Drugs / ELAPEGADEMASE
ELAPEGADEMASE
also known as
Elapegademasa · Elapegademase lvlr · EZN-2279 · PEG-rADA · Polyethylene Glycol Recombinant Adenosine Deaminase · Revcovi
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01420627 | Jan 2014 → Apr 2018 | severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-negative, due to adenosine deaminase deficiency | Leadiant Biosciences, Inc. | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ELAPEGADEMASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990026 ↗ |
| Known as | Elapegademasa | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990026 ↗ |
| Known as | Elapegademase lvlr | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990026 ↗ |
| Known as | EZN-2279 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01420627 ↗ |
| Known as | PEG-rADA | “A Study of EZN-2279 (Polyethylene Glycol Recombinant Adenosine Deaminase [PEG-rADA]) Administered as a Weekly Intramuscular Injection in Patients With Adenosine Deaminase...” NCT01420627 ↗ |
| Known as | Polyethylene Glycol Recombinant Adenosine Deaminase | “A Study of EZN-2279 (Polyethylene Glycol Recombinant Adenosine Deaminase [PEG-rADA]) Administered as a Weekly Intramuscular Injection in Patients With Adenosine Deaminase...” NCT01420627 ↗ |
| Known as | Revcovi | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990026 ↗ |
| Modality | Protein / enzyme biologic | “Polyethylene Glycol Recombinant Adenosine Deaminase [PEG-rADA]” NCT01420627 ↗ |
| Route | Intramuscular | “Weekly administration of EZN-2279 via IM injection” NCT01420627 ↗ |